To Degrade or Not to Degrade DNMT3A

Yuhong Ma; Britta Will

doi:10.1158/2159-8290.CD-21-1430

To Degrade or Not to Degrade DNMT3A

Research output: Contribution to journal › Article › peer-review

Abstract

Aberrant DNA cytosine methylation is a critical contributor to compromised tissue regeneration and malignant transformation, particularly during aging. In this issue of Cancer Discovery, Huang and colleagues define a new class of disease-associated DNA (cytosine-5-)-methyltransferase 3 alpha (DNMT3A) variants with decreased de novo DNA methylation activity due increased proteasomal degradation that are able to drive clonal expansion of hematopoietic stem cells. See related article by Huang et al., p. 220 (5).

Original language	English (US)
Pages (from-to)	23-25
Number of pages	3
Journal	Cancer discovery
Volume	12
Issue number	1
DOIs	https://doi.org/10.1158/2159-8290.CD-21-1430
State	Published - Jan 2022

ASJC Scopus subject areas

Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1158/2159-8290.CD-21-1430

Cite this

@article{ea0ccf111a714b30ad523f2161844dc1,

title = "To Degrade or Not to Degrade DNMT3A",

abstract = "Aberrant DNA cytosine methylation is a critical contributor to compromised tissue regeneration and malignant transformation, particularly during aging. In this issue of Cancer Discovery, Huang and colleagues define a new class of disease-associated DNA (cytosine-5-)-methyltransferase 3 alpha (DNMT3A) variants with decreased de novo DNA methylation activity due increased proteasomal degradation that are able to drive clonal expansion of hematopoietic stem cells. See related article by Huang et al., p. 220 (5).",

author = "Yuhong Ma and Britta Will",

note = "Publisher Copyright: {\textcopyright} 2022 American Association for Cancer Research.",

year = "2022",

month = jan,

doi = "10.1158/2159-8290.CD-21-1430",

language = "English (US)",

volume = "12",

pages = "23--25",

journal = "Cancer discovery",

issn = "2159-8274",

publisher = "American Association for Cancer Research Inc.",

number = "1",

}

TY - JOUR

T1 - To Degrade or Not to Degrade DNMT3A

AU - Ma, Yuhong

AU - Will, Britta

PY - 2022/1

Y1 - 2022/1

N2 - Aberrant DNA cytosine methylation is a critical contributor to compromised tissue regeneration and malignant transformation, particularly during aging. In this issue of Cancer Discovery, Huang and colleagues define a new class of disease-associated DNA (cytosine-5-)-methyltransferase 3 alpha (DNMT3A) variants with decreased de novo DNA methylation activity due increased proteasomal degradation that are able to drive clonal expansion of hematopoietic stem cells. See related article by Huang et al., p. 220 (5).

AB - Aberrant DNA cytosine methylation is a critical contributor to compromised tissue regeneration and malignant transformation, particularly during aging. In this issue of Cancer Discovery, Huang and colleagues define a new class of disease-associated DNA (cytosine-5-)-methyltransferase 3 alpha (DNMT3A) variants with decreased de novo DNA methylation activity due increased proteasomal degradation that are able to drive clonal expansion of hematopoietic stem cells. See related article by Huang et al., p. 220 (5).

UR - http://www.scopus.com/inward/record.url?scp=85123566391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85123566391&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-21-1430

DO - 10.1158/2159-8290.CD-21-1430

M3 - Article

C2 - 35022208

AN - SCOPUS:85123566391

SN - 2159-8274

VL - 12

SP - 23

EP - 25

JO - Cancer discovery

JF - Cancer discovery

IS - 1

ER -

To Degrade or Not to Degrade DNMT3A

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this